Brief Reports
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 1, 2004; 10(15): 2292-2294
Published online Aug 1, 2004. doi: 10.3748/wjg.v10.i15.2292
Effect of octreotide on human pancreatic cancer cells after transfected with somatostatin receptor type 2 gene
Zheng-Ren Liu, Ren-Yi Qin, Gao-Song Wu, Qing Chang, Da-Yu Wang, Sheng-Quan Zou, Fa-Zu Qiu
Zheng-Ren Liu, Ren-Yi Qin, Gao-Song Wu, Qing Chang, Da-Yu Wang, Sheng-Quan Zou, Fa-Zu Qiu, Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: All authors contributed equally to the work.
Supported by the Natural Science Foundation of Hubei Province, No. 2000J068
Correspondence to: Professor Ren-Yi Qin, Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China. ryqin@tjh.tjmu.edu.cn
Telephone: +86-27-83662389
Received: October 27, 2003
Revised: December 3, 2003
Accepted: December 16, 2003
Published online: August 1, 2004
Abstract

AIM: To observe the effect of octreotide on apoptosis rate of human pancreatic cancer cells PC-3 after transfected with somatostatin receptor type 2 (SST2) gene.

METHODS: SST2 plasmid was transfected into PC-3 cells by liposome. Result of transfection was detected by immunocytochemical staining and Western blotting. Apoptosis rates of PC-3 cells under different dosages of octreotide were measured by MTT assay and flow cytometry (FCM).

RESULTS: Apoptosis rate caused by octreotide of transfected PC-3 cells was 7.56 ± 1.06% at the dosage of 0.20 μg/mL, 9.25 ± 1.73% at the dosage of 0.40 μg/mL and 14.18 ± 2.71% at the dosage of 0.80 μg/mL. Apoptosis rate caused by octreotide of non -transfected PC-3 cells was 5.76 ± 0.75% at the dosage of 0.20 μg/mL, 6.69 ± 0.80% at the dosage of 0.40 μg/mL and 7.26 ± 1.28% at the dosage of 0.80 μg/mL. Transfected PC-3 cells growth inhibition rate caused by octreotide was 9.36 ± 1.34% at the dosage of 0.20 μg/mL, 12.03 ± 1.44% at the dosage of 0.40 μg/mL and 20.23 ± 4.21% at the dosage of 0.80 μg/mL. Non-transfected PC -3 cells growth inhibition rate caused by octreotide was 6.44 ± 0.66% at the dosage of 0.20 μg/mL, 7.65 ± 0.88% at the dosage of 0.40 μg/mL and 9.29 ± 1.32% at the dosage of 0.80 μg/mL. We found that octreotide caused higher apoptosis rate and inhibition rate in transfected groups than in non-transfected groups (P < 0.05) at the tested dosages (0.20, 0.40 and 0.80 μg/mL).

CONCLUSION: Deficiency of SST2 was probably the major reason why octreotide had little effect on PC-3 cells. Transfecting SST2 gene could strengthen the ability of octreotide of killing PC-3 cells. It provided an experimental evidence for using both octreotide and transfection with SST2 gene on clinical treatment of pancreatic cancer.

Keywords: $[Keywords]